Sino Biopharmaceutical Limited (SBHMY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sino Biopharmaceutical Limited (SBHMY) trades at $12.68 with AI Score 54/100 (Grade B). Sino Biopharmaceutical Limited is a leading pharmaceutical conglomerate in China, focusing on research and development across various therapeutic areas. Market cap: $11.27B, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for SBHMY: SBHMY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SBHMY against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SBHMY: 4/6 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Sino Biopharmaceutical Limited (SBHMY) Healthcare & Pipeline Overview
Sino Biopharmaceutical Limited is a prominent player in the Chinese biotechnology sector, specializing in modernized Chinese medicines and chemical pharmaceuticals, with a robust product lineup that addresses critical healthcare needs across oncology, cardiology, and more.
What Is the Investment Thesis for SBHMY?
Sino Biopharmaceutical Limited presents a compelling investment thesis driven by its robust market position and diverse product portfolio. The company has a market capitalization of approximately $12.74 billion and a P/E ratio of 28.4, indicating strong investor confidence. Its gross margin stands at an impressive 82.1%, reflecting efficient operations and pricing power in the competitive biotechnology landscape. Key growth catalysts include the increasing demand for oncology and chronic disease treatments in China, alongside ongoing investments in research and development, which are expected to enhance its product pipeline. Furthermore, the company's strategic focus on modernized Chinese medicines positions it to capture a significant share of the market as healthcare spending continues to rise. However, potential risks include regulatory challenges and competition from both domestic and international players. Overall, Sino Biopharmaceutical's strong fundamentals and growth strategy make it an attractive candidate for institutional investment.
Based on FMP financials and quantitative analysis
SBHMY Key Highlights
- Market cap of $11.27B reflects strong investor confidence in the company's growth potential.
- P/E ratio of 28.4 indicates favorable valuation compared to industry peers.
- Profit margin of 7.4% showcases effective cost management and operational efficiency.
- Gross margin of 82.1% significantly exceeds the industry average, highlighting pricing power.
- Dividend yield of 1.91% provides a return to shareholders amidst growth investments.
Who Are SBHMY's Competitors?
SBHMY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALPMF Astellas Pharma Inc. | $14.60 | +3.18% | $26.16B | 58 |
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| SAUHF Straumann Holding AG | $131.11 | -2.88% | $20.91B | 52 |
| WXIBF WuXi Biologics (Cayman) Inc. | $4.63 | -1.07% | $19.18B | 49 |
| IVBXF Innovent Biologics, Inc. | $11.39 | +3.02% | $19.76B | 68 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SBHMY's Key Strengths?
- Extensive product range addressing critical healthcare needs.
- Strong gross margin indicating operational efficiency.
- Established market presence in China with a large workforce.
- Commitment to R&D driving innovation and growth.
What Are SBHMY's Weaknesses?
- Dependence on the Chinese market for revenue.
- Potential regulatory challenges impacting product approvals.
- Limited international presence compared to global competitors.
- Vulnerability to pricing pressures in a competitive market.
What Could Drive SBHMY Stock Higher?
- Launch of new oncology products expected in Q4 2026, enhancing market presence.
- Expansion of distribution channels across China to increase market penetration.
- Strategic partnerships with healthcare providers to enhance service offerings.
- Regulatory approvals for new drugs anticipated in late 2026, potentially boosting revenues.
- Increased investment in R&D to drive innovation and product development.
What Are the Key Risks for SBHMY?
- Regulatory changes that could impact product approvals and market access.
- Intense competition from domestic and international pharmaceutical companies.
- Economic fluctuations affecting healthcare spending in China.
- Patent expirations leading to increased competition from biosimilars.
What Are the Growth Opportunities for SBHMY?
- Expansion in Oncology: The global oncology market is projected to reach $200 billion by 2026, driven by increasing cancer prevalence and advancements in treatment. Sino Biopharmaceutical's strong portfolio in oncology medicines, including Qingkeshu tablets and Anxian capsules, positions it to capture a significant share of this growing market, especially as healthcare spending in China continues to rise.
- Development of Cardio-Cerebral Vascular Medicines: With cardiovascular diseases being a leading cause of mortality in China, the market for related treatments is expanding rapidly. Sino Biopharmaceutical's offerings, such as Kaina and Anrixin tablets, are well-positioned to meet this demand, supported by ongoing R&D efforts to enhance their efficacy and reach.
- Investment in Research and Development: Sino Biopharmaceutical's commitment to R&D is a key growth driver, with significant investments aimed at developing innovative therapies and expanding its product pipeline. This focus is expected to yield new products that address unmet medical needs, further solidifying its market position.
- Geographic Expansion: As Sino Biopharmaceutical continues to strengthen its foothold in the Chinese market, there are opportunities for geographic expansion into other emerging markets. This strategy could enhance revenue streams and diversify its market presence, capitalizing on the growing demand for healthcare solutions globally.
- Acquisitions and Partnerships: Strategic acquisitions and partnerships can provide Sino Biopharmaceutical with access to new technologies and markets. By leveraging its financial strength and market expertise, the company can enhance its competitive edge and accelerate growth through synergistic collaborations.
What Opportunities Does SBHMY Have?
- Growing demand for oncology and chronic disease treatments.
- Potential for geographic expansion into emerging markets.
- Strategic acquisitions to enhance product offerings and market reach.
- Increasing healthcare spending in China providing growth potential.
What Threats Does SBHMY Face?
- Intense competition from domestic and international pharmaceutical companies.
- Regulatory changes impacting the pharmaceutical landscape.
- Patent expirations leading to increased biosimilar competition.
- Economic fluctuations affecting healthcare spending.
What Are SBHMY's Competitive Advantages?
- Strong R&D capabilities that drive innovation and product development.
- Diverse product portfolio addressing various therapeutic areas, reducing dependency on any single product.
- Established brand reputation in the Chinese pharmaceutical market, fostering customer loyalty.
- Strategic partnerships and collaborations enhancing market reach and technological capabilities.
- Robust distribution network ensuring efficient product delivery and availability.
What Does SBHMY Do?
Sino Biopharmaceutical Limited, established in 2000 and headquartered in Wan Chai, Hong Kong, operates as a research and development-driven pharmaceutical conglomerate primarily in the People's Republic of China. The company has evolved significantly since its inception, focusing on three main segments: Modernised Chinese Medicines, Chemical Medicines, and Investment. Its extensive product range includes oncology medicines such as Qingkeshu tablets and Anxian capsules, cardio-cerebral vascular medicines like Kaina and Anrixin tablets, and hepatitis treatments including Tianqingganmei injections. Additionally, it offers a variety of orthopedic, respiratory, and parenteral nutrition medicines. Beyond pharmaceuticals, Sino Biopharmaceutical also engages in property holdings, retailing pharmaceutical products, operating hospitals, and providing consultancy services in medical management and health information. The company's commitment to innovation is reflected in its ongoing research and development efforts, which aim to enhance its product offerings and expand its market reach. With a workforce of approximately 24,379 employees, Sino Biopharmaceutical is well-positioned to capitalize on the growing demand for healthcare solutions in China and beyond, leveraging its expertise in both traditional and modern medicine.
What Products and Services Does SBHMY Offer?
- Develop and manufacture a wide range of pharmaceutical products, including oncology and cardiovascular medicines.
- Engage in research and development to innovate new therapies and improve existing products.
- Operate hospitals and provide healthcare services, enhancing patient care and treatment options.
- Retail and distribute pharmaceutical products across various channels in China.
- Offer consultancy services in medical management and health information.
- Manufacture and sell health food and medical devices.
How Does SBHMY Make Money?
- Generate revenue through the sale of pharmaceutical products across multiple therapeutic areas.
- Leverage R&D investments to develop new drugs and therapies, enhancing product offerings.
- Operate hospitals and provide healthcare services, creating additional revenue streams.
- Engage in property holdings and retail distribution of pharmaceutical products.
- Provide consultancy services, generating income from healthcare management and technology transfer.
What Industry Does SBHMY Operate In?
The biotechnology industry in China is experiencing rapid growth, driven by increasing healthcare expenditures and a rising demand for innovative treatments. Sino Biopharmaceutical Limited operates in a competitive landscape, facing rivals such as Astellas Pharma Inc. (ALPMF), Orion Oyj (ORINY), and WuXi Biologics (WXIBF). The market for biopharmaceuticals is expected to expand significantly, with a projected CAGR of over 15% in the coming years. Sino Biopharmaceutical's focus on modernized Chinese medicines positions it uniquely within this growing market, allowing it to leverage traditional medicine practices alongside modern pharmaceutical innovations.
Who Are SBHMY's Key Customers?
- Hospitals and healthcare providers seeking innovative pharmaceutical solutions.
- Patients requiring specialized medications for chronic diseases and conditions.
- Pharmacies and distributors looking for a reliable source of pharmaceutical products.
- Healthcare institutions seeking consultancy and management services.
- Government and private organizations involved in healthcare procurement.
How Sino Biopharmaceutical Limited Is Valued
Sino Biopharmaceutical Limited carries a market capitalization of $11.27B, placing it in the large-cap category. Relative to its peer group, SBHMY's quantitative score of 54/100 is roughly in line with the peer average of 58/100.
Company Profile
Sino Biopharmaceutical Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Wan Chai, HK. The company is led by CEO S. Y. Tse. SBHMY has traded publicly since 2017.
ROE 7%Key Financial Metrics
Return on equity for Sino Biopharmaceutical Limited stands at 7.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.1%, showing how much profit it generates from its asset base. SBHMY trades at a trailing price-to-earnings ratio of 28.38, above the Healthcare sector average of ~23x. Its free cash flow yield is 4.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.37 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
Sino Biopharmaceutical Limited's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.61 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project Sino Biopharmaceutical Limited revenue of about $36.02B for fiscal 2026, with EPS near $0.00. The estimate reflects 19 contributing analysts.
SBHMY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying could signal confidence in the company's future prospects, suggesting those with inside knowledge believe the stock is undervalued.
- Positive community sentiment indicates a belief in Sino Biopharmaceutical's long-term growth potential and strategic direction.
- The company's focus on innovative drug development may position it favorably in the competitive pharmaceutical landscape, attracting investor interest.
- Overall market perception seems to be improving, potentially driven by positive news or developments within the broader healthcare sector.
Bear Case
- Increased selling activity by insiders might suggest concerns about the company's near-term performance or market conditions.
- Negative sentiment within the trading community could reflect worries about regulatory hurdles or competitive pressures facing Sino Biopharmaceutical.
- Unfavorable market perception, possibly stemming from negative news or industry trends, could weigh on investor confidence.
- Recent market developments, such as increased competition or changing healthcare policies, might pose challenges to the company's growth trajectory.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SBHMY Latest News
No recent news available for SBHMY.
SBHMY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SBHMY.
Price Targets
Wall Street price target analysis for SBHMY.
SBHMY MoonshotScore
What does this score mean?
The MoonshotScore rates SBHMY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: S. Y. Tse
CEO
S. Y. Tse has been a pivotal figure in Sino Biopharmaceutical Limited, bringing extensive experience in the pharmaceutical industry. With a strong educational background and a track record of leadership, he has guided the company through significant growth phases. Prior to his role at Sino Biopharmaceutical, Tse held various leadership positions in other pharmaceutical companies, where he honed his expertise in operations and strategic management.
Track Record: Under S. Y. Tse's leadership, Sino Biopharmaceutical has expanded its product portfolio and strengthened its market position in China. His strategic focus on R&D and innovation has led to the successful launch of several key products, enhancing the company's reputation in the biotechnology sector.
Sino Biopharmaceutical Limited ADR Information Unsponsored
An American Depositary Receipt (ADR) is a financial instrument that represents shares in a foreign company, allowing U.S. investors to trade shares without dealing with foreign currencies. Sino Biopharmaceutical Limited's ADR, SBHMY, enables investors to access its shares listed on the OTC market while being denominated in U.S. dollars.
- Home Market Ticker: Hong Kong Stock Exchange (SBHM)
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: SBHM
SBHMY OTC Market Information
The OTC Other tier includes securities that do not meet the requirements for listing on major exchanges like the NYSE or NASDAQ. This tier often features companies that have lower trading volumes and may not provide the same level of transparency as listed companies, potentially impacting investor confidence.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity can lead to price volatility and difficulty in executing large trades.
- Potential lack of transparency in financial reporting compared to listed companies.
- Increased susceptibility to market manipulation due to lower regulatory oversight.
- Foreign exchange risks impacting returns for U.S. investors.
- Verify the company's financial health through available reports.
- Assess the competitive landscape and market positioning.
- Review recent news and developments affecting the company.
- Understand the regulatory environment in which the company operates.
- Evaluate the management team's track record and experience.
- Established history since 2000 with a significant employee base.
- Presence on the Hong Kong Stock Exchange, providing a level of credibility.
- Diverse product portfolio addressing critical healthcare needs.
- Commitment to R&D and innovation in the pharmaceutical sector.
What Investors Ask About Sino Biopharmaceutical Limited (SBHMY) — Healthcare
What does Sino Biopharmaceutical Limited do?
Sino Biopharmaceutical Limited is a leading pharmaceutical company in China, focusing on research and development across various therapeutic areas. It develops and manufactures a wide range of products, including oncology, cardiovascular, and orthopedic medicines, while also engaging in healthcare services and consultancy.
What do analysts say about SBHMY stock?
Analysts generally view Sino Biopharmaceutical Limited favorably, citing its strong market position and diverse product offerings. Key valuation metrics indicate a P/E ratio of 28.4 and a gross margin of 82.1%, suggesting robust financial health. Growth considerations include the increasing demand for healthcare solutions in China.
What are the main risks for SBHMY?
Sino Biopharmaceutical Limited faces several risks, including regulatory challenges that could impact product approvals and market access. Additionally, intense competition from both domestic and international pharmaceutical companies poses a threat to market share. Economic fluctuations may also affect healthcare spending, impacting revenue growth.
What are the key factors to evaluate for SBHMY?
Sino Biopharmaceutical Limited (SBHMY) holds an AI score of 54/100 (moderate). P/E: 28.4x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does SBHMY data refresh on this page?
SBHMY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SBHMY's recent stock price performance?
Sino Biopharmaceutical Limited (SBHMY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive product range addressing critical healthcare needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SBHMY overvalued or undervalued right now?
Sino Biopharmaceutical Limited (SBHMY) trades at 28.4x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SBHMY?
Before investing in Sino Biopharmaceutical Limited (SBHMY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data sourced from company reports and financial metrics.